The Latest News
Tullis Growth Fund, L.P. Makes An Investment into SureFire
In June 2015, Tullis Growth Fund, L.P. (TGF) closed an investment into Surefire Medical. The company develops, manufactures, and markets medical devices, in particular catheters to precisely deliver therapeutic drugs in liver cancer patients. The goal of the Surefire delivery system is to increase the concentration of cancer drugs/embolization agents in the tumor while decreasing the uptake of these toxic agents in surrounding healthy tissue. Surefire has achieved US FDA approval and a running rate in revenue approaching $5 million per year. Surefire devices may have utility in other forms of cancer and other disease states pursuant to research currently underway.
“The Tullis group's deep expertise in healthcare and medical devices in particular will be instrumental in realizing the broad potential of Surefire Medical's first in class technology for precision delivery of embolics to treat primary and secondary liver tumors, and possibly other conditions," said James E. Chomas, President and CEO of Surefire Medical. "The Tullis team is highly respected by our Board, and I am excited to work closely with new Board member John Tullis to drive growth in the our existing markets as well as in China. As clinical evidence continues to mount showing our drug delivery technology increases uptake by tumors while sparing healthy tissue, we welcome his team's expertise and track record of successfully helping guide the growth of innovative companies such as ours."
The Surefire system is used in over 100 hospitals in the US and in 14 countries around the world. It has been clinically proven to improve tumor penetration and to reduce procedure time in liver cancer.